Townsend C M, Eilber F R, Morton D L
JAMA. 1976 Nov 8;236(19):2187-9.
Because there is evidence for an active immunologic response against sarcoma, a clinical trial of adjuvant immunotherapy using bacillus Calmette-Guérin (BCG) and tumor cell vaccine was begun. Eleven of 18 patients with localized soft tissue sarcoma who received immunotherapy are free of disease, compared to only 5 of 15 treated by operation alone who are free of disease. Furthermore, immunotherapy also prolonged the median disease-free interval from 7.3 months to 15 months in the patients who experienced recurrence of their disease.
由于有证据表明机体对肉瘤存在活跃的免疫反应，因此开展了一项使用卡介苗（BCG）和肿瘤细胞疫苗的辅助免疫治疗临床试验。接受免疫治疗的18例局限性软组织肉瘤患者中有11例无疾病，而仅接受手术治疗的15例患者中只有5例无疾病。此外，免疫治疗还将疾病复发患者的无病间隔中位数从7.3个月延长至15个月。
